The National Scleroderma Foundation has recognized several individuals — leaders in advocacy, fundraising, and patient support — and regional chapters for their service in advancing scleroderma awareness and research. The 12 awards, given at the 2025 National Scleroderma Conference, held July 18-20 in St. Louis, were given for…
The Scleroderma Research Foundation (SRF) announced that it has joined Vie Ventures to advance research and accelerate the development of innovative therapies for scleroderma and other autoimmune diseases. The venture capital firm unites biotech investors with autoimmune disease organizations to fund the translation of scientific discoveries into…
Scientists in China have identified four distinct subtypes of systemic sclerosis-associated interstitial lung disease (SSc-ILD), each characterized by different clinical characteristics, a new study found. With these four subtypes identified, the team then analyzed outcomes for each subtype and found differing survival rates and factors associated with mortality, which…
Galderma is launching a Phase 2 clinical trial to test nemolizumab, an antibody the company is developing to ease inflammation and scarring, known medically as fibrosis, in systemic sclerosis (SSc). Recruitment is planned to begin in North America, South America, and Europe in the second half of this…
Levels of certain types of immune cells are abnormally high in some people with systemic sclerosis (SSc), and this may be linked to serious kidney and lung complications — such as renal crisis and interstitial lung disease (ILD) — according to a study of blood cells from patients.
Two patients with systemic sclerosis (SSc) had reduced skin thickness after treatment with the investigational CAR T-cell therapy rese-cel (resecabtagene autoleucel) and discontinuation of immunomodulators and steroids. These initial results came from the Phase 1/2 RESET-SSc clinical trial (NCT06328777), one of several trials that rese-cel developer…
The onset of pulmonary hypertension (PH), or high blood pressure in the lungs, may be a critical factor in predicting disease progression and poorer survival in systemic sclerosis (SSc), a study from France suggests. By grouping patients based on internal organ involvement, rather than relying on traditional classifications…
June is Scleroderma Awareness Month, and the scleroderma community is kicking into gear to spread awareness about the rare, chronic disorder. The National Scleroderma Foundation has selected “Stories of Strength” as this year’s theme, encouraging people with scleroderma to share their stories about how the disease has affected…
Most people with systemic sclerosis (SSc) have fibrosis, or scarring, that affects the heart muscle, a study in Australia shows. In two-thirds of the cases, heart fibrosis had no other, or secondary, cause, helping to explain mortality and sudden cardiac death in these patients, according to the researchers. Lung…
Lung function decline among people with systemic sclerosis-associated interstitial lung disease (SSc-ILD) was significantly slowed over the course of about four years of treatment with Ofev (nintedanib), according to a new analysis of trial data. The analysis was based on changes in forced vital capacity, or FVC, a measure…
Get regular updates to your inbox.